Computer-Aided Discovery of Small Molecule Inhibitors of Thymocyte Selection-Associated High Mobility Group Box Protein (TOX) as Potential Therapeutics for Cutaneous T-Cell Lymphomas. This evidence concerns the gene TOX and primary cutaneous T-cell non-Hodgkin lymphoma.